Carlyle and SK Capital Partners are buying beleaguered gene therapy biotech Bluebird Bio for about $29 million.

Up to 40% of patients with inflammatory bowel disease (IBD) experience extraintestinal manifestations (EIMs), with the ...

"We're taking decisive action to contain these massive cost increases while maintaining quality of care for the Hoosiers that ...

Regeneron Pharmaceuticals said on Monday its experimental gene therapy showed improved hearing in 10 of 11 children between ...

In January 2025, various US Food and Drug Administration (FDA) centers and offices published their guidance agendas for the 2025 calendar year ...

Regeneron’s gene therapy, dubbed DB-OTO, is a cell-selective AAV gene therapy for children with hearing loss stemming from a ...

Orismilast may be an effective and safe novel treatment option for adult patients with moderate to severe atopic dermatitis.

Here's why a gene therapy product originally developed at CHOP spinout Spark Therapeutics was shelved by Pfizer.

The addition of itacitinib to standard graft-versus-host-disease prophylaxis may reduce severe toxicities following ...

ASCO’s updated guidelines for advanced ovarian cancer emphasize health equity and provide new recommendations for HIPEC while ...

“Pope Francis is touched by the numerous messages of affection and closeness that he continues to receive in these hours,” ...

Ketamine, a dissociative anesthetic, has carved itself a spot in the world of mental health care over the past two decades.